Cardiology Topic Homepage

Heart Failure

Heart Failure

Heart Failure is a progressive chronic disorder that results in the inability of the heart to pump blood efficiently to the body’s tissues.

Chronic heart failure is an increasing public health problem; the growing prevalence in industrialised countries means that 1-2% of the adult population of these countries are now thought to have chronic heart failure.1-3 Estimates suggest that the prevalence in Europe, USA and Japan could increase by approximately 16.5% over the next ten years.4

The prevalence of post-myocardial infarction heart failure is less well known as it is difficult to distinguish between pre-existing and incident heart failure. However current estimates suggest that approximately 1 in 5 patients hospitalised with an acute coronary syndrome either present with heart failure or develop heart failure during their hospital stay.5

Many of the signs and symptoms of heart failure are non-specific and vary in severity depending on the disease class. The most common of these are breathlessness, fatigue, exercise intolerance, and fluid retention as evidenced by ankle swelling, peripheral oedema, and an elevated jugular venous pressure.6

Due to the non-specific nature of symptoms, the diagnosis of heart failure can be difficult. Tests can include echocardiogram, ECG, chest X-ray, laboratory tests. Following a positive diagnosis heart failure is classified into functional classes that relate to disease severity.

Management of heart failure involves lifestyle modifications, pharmacological treatment and occasionally surgery. In patients with chronic heart failure, optimal therapy involves treatment with diuretics, ACE inhibitors, certain β-blockers and a mineralocorticoid receptor antagonist.

The Heart Failure Knowledge Centre brings together current information related to chronic heart failure and post-myocardial infarction, including:

  • Epidemiology
  • Symptoms and Diagnosis
  • Classification
  • Treatment Options

Enter the Heart Failure Knowledge Centre


References

  1. Zannad F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Journal of the American College of Cardiology 1999; 33(3):734-742.
  2. Cowie MR, et al. The epidemiology of heart failure. European Heart Journal 1997;18(2):208-225.
  3. Mosterd A, Hoes A. Clinical epidemiology of heart failure. Heart 2007; 93:1137-1146.
  4. Decision Resources. Chronic Heart Failure. Cardium Study No.4 A Pharmacor Service. 2008.
  5. Steg PG, Dabbous OH, et al. Determinants and prognostic impact of heart failure complicating acutecoronary syndromes. Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation2004;109:494-9.
  6. NICE Clinical Guideline No 108. Chronic Heart Failure. National clinical guideline for diagnosis and management in primary and secondary care. 2010.

Type 2 Diabetes Knowledge Centre

Type 2 Diabetes Knowledge Centre

The Type 2 Diabetes Knowledge Centre has been developed with the aim of providing clear and concise information based on current accepted guidelines on treatment and management.

The leading cause of morbidity and mortality among patients with Type 2 diabetes mellitus is cardiovascular complications with cardiovascular disease risk being 2- to 8-fold higher in the diabetic population than it is in non-diabetic individuals of a similar age, sex and ethnicity.1,2

Macrovascular complications (including coronary artery disease, peripheral arterial disease and stroke, and microvascular complications (including diabetic nephropathy, peripheral neuropathy and diabetic retinopathy), are collectively known as diabetic vascular complications commonly developed in patients with Type 2 diabetes mellitus.3 The correlation between insulin resistance and cardiovascular disease has been demonstrated in several clinical studies.4,5

Further information on the cardiovascular complications associated with Type 2 diabetes mellitus can be found in the Knowledge Centre.


References

  1. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
  2. Brun E, Nelson NG, Bennett PH et al. Verona Diabetes Study. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 2000;23:1119-1123.
  3. Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabetic Studies 2012;9:6-22.
  4. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
  5. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Arterial disease/hypertension/angiotensin system: non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC study. Circulation 1995;91:1432-1443.

Clinical Case Studies

MRSA Endocarditis

Infection: Cardiovascular Infections

Christopher D. Pfeiffer, Clinical Fellow, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
Vance Fowler, Associate Professor and Infectious Diseases, Specialist, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

Case History
A 64-year-old female presented with three weeks of progressive dyspnoea, nausea and vomiting.

Vascular Graft Infection

Infection: Cardiovascular Infections

Stephanie J. Dancer BSc, MB BS, MSc, MD, FRCPath, DTM&H, Consultant Microbiologist, NHS Lanarkshire, Scotland

Case History
A 72-year-old man was referred by his general practitioner complaining of intermittent pain in the legs on exercise.

Medical Videos

A Discussion of Interventional Cardiology and the Procedures Involved
A Discussion of Interventional Cardiology and the Procedures Involved
A Guide to the Coronary Angioplasty Procedure
A Guide to the Coronary Angioplasty Procedure
3D Medical Animation - Congestive Heart Failure
3D Medical Animation - Congestive Heart Failure
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
Animation: New therapy prevents heart failure
Animation: New therapy prevents heart failure
The Lead: Time to Abandon LDL Treatment Targets?
The Lead: Time to Abandon LDL Treatment Targets?

Recent Drug Updates

Clinical Guidelines

MI – secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction

Nov 2013

This guideline offers best practice advice on the care of adults who have had a myocardial..

... infarction.

Unstable angina and NSTEMI

Nov 2013

The term ‘acute coronary syndromes’ encompasses a range of conditions from unstable angina to..

... ST-segment-elevation myocardial infarction (STEMI), arising from thrombus formation on an atheromatous plaque. This guideline addresses the early management of unstable angina and non-ST-segment-elevation myocardial infarction (NSTEMI) once a firm diagnosis has been made and before discharge from hospital. If untreated, the prognosis is poor and mortality high, particularly in people who have had myocardial damage. Appropriate triage, risk assessment and timely use of acute pharmacological or invasive interventions are critical for the prevention of future adverse cardiovascular events (myocardial infarction, stroke, repeat revascularisation or death).

Clinical Trials

Imaging Control Study, 3D Echo, MR and RHC. (PARIS)

22-07-2014

The aim of the study is to intensify the follow up of patients with pulmonary arterial hypertension via modern imaging guided methods in due consideration of the possibilities of three-dimensional echocardiography in order to optimize their specific therapy.

The hypothesis is that the increased use of..

... modern imaging guided tools is essential for the follow up.

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

21-07-2014

This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

Back to top